Consistent with this effect of ASXL1 mutations, we found that they commonly occurred in drug-resistant AML cells, both in samples with high and low levels of expression of other genes at 20q11-q13.32 that were associated with response to the same agents in our analysis (Additional file 12: Fig. S4). The gene discussed is ASXL1; the disease is acute myeloid leukemia.